AndroGel vs Jatenzo: Cost and Access Head-to-Head

Why This Comparison Matters for TRT Patients

Men starting testosterone replacement therapy (TRT) for confirmed hypogonadism face a practical question before any clinical one: can I afford this medication month after month, and will my plan cover it? AndroGel and Jatenzo represent two fundamentally different delivery routes, topical versus oral, and the cost gap between them can exceed $600 per month depending on insurance status.

The Formulary Reality

Most pharmacy benefit managers (PBMs) place generic testosterone gel on preferred tiers because the patents expired years ago. Jatenzo, approved by the FDA in March 2019, remains branded with no authorized generic. That distinction alone drives the majority of the cost difference patients see at the pharmacy counter. According to the Endocrine Society's 2018 clinical practice guideline, the choice among testosterone formulations should factor in "patient preference, pharmacokinetics, treatment burden, and cost" [3]. The guideline does not rank one formulation above another for efficacy.

Who Should Read This

This article is for men with a confirmed diagnosis of hypogonadism (two morning total testosterone levels below 300 ng/dL per the Endocrine Society threshold) who are comparing these two specific medications. If you have not been diagnosed, this comparison is premature. Get lab work first.

Clinical Efficacy: How They Compare

Both AndroGel and Jatenzo restore serum testosterone to the eugonadal range (300 to 1,000 ng/dL) in most men. No published head-to-head randomized controlled trial directly compares these two products. The comparison below draws on separate key studies.

AndroGel: The T-Trials Evidence

The landmark Testosterone Trials (TTrials) enrolled 790 men aged 65 and older with serum testosterone below 275 ng/dL. Men randomized to 1% testosterone gel applied daily achieved and sustained serum testosterone in the normal range over 12 months [1]. The study demonstrated improvements in sexual function, walking distance, and mood. Bone mineral density increased in a substudy. These results established topical testosterone gel as a well-characterized option with over a decade of post-market safety data.

Jatenzo: The Swerdloff Oral TRT Data

Swerdloff et al. (2020) published the key phase 3 trial for Jatenzo, enrolling 166 hypogonadal men. At the 3-month primary endpoint, 87% of patients achieved a serum testosterone average within the eugonadal range (between 300 and 1,100 ng/dL) [2]. The drug uses a self-emulsifying formulation absorbed through the intestinal lymphatic system, bypassing first-pass liver metabolism. That lymphatic absorption pathway is what distinguishes Jatenzo from older oral methyltestosterone products, which carried hepatotoxicity risks and fell out of favor.

Interpreting Cross-Trial Numbers

Both drugs normalize testosterone. The 87% response rate for Jatenzo and the consistent normalization seen in T-Trials are not directly comparable because trial designs, patient populations, and outcome definitions differed. Clinicians generally consider the two products equivalent in their ability to restore hormone levels, with the route of delivery, safety profile, and cost acting as the real differentiators.

Cost Breakdown: What You Will Actually Pay

The financial gap between these two medications is the single biggest factor driving prescribing patterns. Here is what the numbers look like in mid-2026.

Generic Testosterone Gel

Brand AndroGel 1.62% carries a list price near $700 for a 30-day supply. But very few patients pay that. Generic testosterone gel 1% (available from Teva, Perrigo, and others) costs $30 to $90/month at retail pharmacies with a manufacturer coupon or GoodRx discount. With commercial insurance and Tier 1 placement, copays typically fall between $5 and $30.

Jatenzo Pricing

Jatenzo has a wholesale acquisition cost of approximately $750/month. The manufacturer, Clarus Therapeutics (acquired by Halozyme in 2023), offers a copay savings card that can reduce out-of-pocket costs to as low as $0 for commercially insured patients who meet eligibility criteria. Without the savings card or with Medicare Part D (where copay cards cannot be applied legally), patients may face monthly costs between $150 and $500+ depending on plan design and tier placement.

Medicare and Medicaid Considerations

Generic testosterone gel is on most state Medicaid preferred drug lists. Jatenzo often requires prior authorization under both Medicaid and Medicare Part D. Under Medicare Part D, Jatenzo falls into the specialty tier for many plan formularies, pushing patient cost-sharing into the coverage gap ("donut hole") faster. The FDA label for Jatenzo includes no restrictions on payer type, but formulary placement creates de facto access barriers [4].

Safety Profiles: Different Risks for Different Routes

Both medications carry the class-wide testosterone warnings (polycythemia, cardiovascular risk, sleep apnea worsening), but each has a route-specific concern that matters for everyday life.

AndroGel Transfer Risk

Topical testosterone gel can transfer to others through skin contact. The FDA requires a boxed warning on all testosterone gel products about secondary exposure, particularly to women and children [5]. Virilization in children exposed to testosterone gel through skin contact has been documented in FDA post-market reports. Men who live with young children or a female partner must apply the gel to covered skin areas (upper arms, shoulders) and wash hands immediately. Wearing a shirt over the application site reduces but does not eliminate risk.

Jatenzo Blood Pressure Warning

Jatenzo carries its own FDA boxed warning for increases in blood pressure [4]. In the Swerdloff trial, systolic blood pressure rose by a mean of 3 to 5 mmHg in the treatment group. Men with uncontrolled hypertension (systolic above 140 mmHg or diastolic above 90 mmHg) were excluded from the key trial. The FDA label recommends blood pressure monitoring before starting Jatenzo, at 1 month, then periodically. For men with borderline or Stage 1 hypertension, this is a real clinical consideration, not a theoretical one.

Liver Safety

Jatenzo's lymphatic absorption route avoids the hepatotoxicity associated with older oral androgens like methyltestosterone. In the Swerdloff et al. Trial, liver function tests remained within normal limits throughout the 12-month extension period [2]. This represents a genuine advance over the oral testosterone products of the 1960s through 1990s, which were abandoned in the U.S. Partly because of liver damage.

Insurance Coverage and Prior Authorization

Getting a prescription filled is only half the battle. Getting it covered is the other half.

Tier Placement Patterns

A 2024 JAMA Network analysis of Part D formularies found that generic topical testosterone was on the preferred brand or generic tier of 92% of sampled plans [6]. Jatenzo appeared on only 47% of sampled formularies, and where listed, it sat on Tier 3 (non-preferred brand) or higher in 81% of cases. That tier placement directly translates to higher copays, more prior authorization paperwork, and longer time-to-fill.

Prior Authorization Requirements

Jatenzo prior authorization criteria typically require documentation of:

• Two morning serum total testosterone levels below 300 ng/dL
• Failure or intolerance of at least one topical testosterone product
• No uncontrolled hypertension

The "step therapy" requirement (try topical first, fail, then get oral approved) is the most common barrier. For generic testosterone gel, prior authorization is uncommon on commercial plans and required by only a minority of Medicaid programs.

VA and TRICARE

The VA National Formulary includes generic testosterone gel as a formulary agent. Jatenzo is classified as non-formulary within the VA system, requiring a non-formulary request through the prescribing physician. TRICARE covers generic testosterone gel at Tier 1 copay levels. Jatenzo coverage under TRICARE requires prior authorization and medical necessity documentation, according to the Express Scripts TRICARE formulary search tool.

Convenience and Adherence

How a medication fits into daily life affects whether men stay on it. Adherence to TRT is a documented problem. A 2019 cohort study published in The Journal of Clinical Endocrinology & Metabolism found that roughly 50% of men prescribed topical testosterone discontinued within the first 12 months [7].

Daily Routine With AndroGel

Application takes 2 to 5 minutes each morning. You pump or squeeze the gel onto dry skin (shoulders or upper arms), let it air-dry for 3 to 5 minutes, and wash your hands. You cannot shower or swim for at least 2 hours. The routine is simple but adds friction, especially for men with active morning schedules or young children in the home.

Daily Routine With Jatenzo

Two capsules daily, taken with food. The morning and evening doses should be roughly 12 hours apart. Each dose must accompany a meal containing at least some fat (the lymphatic absorption depends on dietary lipid). Missing a meal or taking it on an empty stomach reduces absorption significantly.

Which Patients Prefer Which

Men who dislike injections and want to avoid topical transfer risk are the primary candidates for Jatenzo. Men who want the lowest possible out-of-pocket cost and don't mind a brief morning routine favor generic gel. Neither option is clearly "better." The Endocrine Society guideline states that "patient preference" should drive formulation choice when efficacy is comparable [3].

Pharmacokinetics: Absorption and Steady-State Differences

Understanding how each drug enters the bloodstream helps explain why dosing and monitoring protocols differ.

Topical Gel Absorption

Testosterone gel creates a reservoir in the skin's stratum corneum. Serum testosterone rises over 2 to 4 hours post-application and reaches steady state after about 2 to 3 days of daily use. The T-Trials protocol adjusted gel dosing based on trough testosterone levels drawn before the morning application [1]. Absorption varies with application site, skin thickness, and perspiration. This variability is the main clinical limitation of the topical route.

Oral Undecanoate Absorption

Jatenzo's self-emulsifying drug delivery system (SEDDS) dissolves in intestinal chyme and enters the lymphatic system, not the portal vein. Peak serum testosterone occurs 4 to 5 hours after an oral dose. The twice-daily dosing schedule creates a pulsatile pattern that roughly mimics the natural diurnal rhythm (higher in the morning, lower at night), though less precisely than injectable testosterone cypionate. In the Swerdloff trial, dose titration (from 237 mg to 158 mg or 316 mg twice daily) was guided by serum testosterone measured 4 to 6 hours post-dose [2].

Monitoring Requirements

Both drugs require the same baseline labs: total testosterone, free testosterone, PSA, CBC (hematocrit), and a lipid panel. The differences emerge after initiation.

Monitoring on Gel

Check serum testosterone (trough, before morning application) at 1 month, 3 months, and then every 6 to 12 months. Hematocrit at 3 months, then annually. No routine blood pressure monitoring specific to the formulation, though standard hypertension screening applies.

Monitoring on Jatenzo

Same lab schedule, but add blood pressure checks at baseline, 1 month, 3 months, 6 months, and annually. The FDA label explicitly requires this. If systolic blood pressure exceeds 140 mmHg on two separate readings, the prescribing information recommends dose reduction or discontinuation [4]. The blood pressure monitoring adds a visit burden that gel does not impose.

Who Should Choose Which

There is no universal answer, but the decision tree is fairly clear.

Choose generic testosterone gel if:

• Cost is a primary concern
• Your insurance covers it at Tier 1 or 2
• You have no young children or female partners with regular skin contact
• You tolerate the daily application routine

Choose Jatenzo if:

• You have documented intolerance or allergy to topical testosterone
• Transfer risk is a real concern (young children in the home, partner sensitivity)
• You prefer an oral medication and are willing to manage prior authorization
• Your blood pressure is well-controlled (below 130/80)
• You have manufacturer copay card eligibility or commercial insurance that covers it

Dr. Ronald Swerdloff, who led the Jatenzo key trial, noted in the study discussion that "an effective oral testosterone that avoids first-pass hepatotoxicity addresses a long-standing unmet need," particularly for men who cannot use or prefer not to use topical or injectable formulations [2].

The American Urological Association's 2018 guideline on testosterone deficiency states: "Clinicians should counsel patients on the lack of evidence of superiority of any one testosterone formulation over another" [8]. That principle holds. The choice is about logistics, not pharmacology.